Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Routine blood tests, biochemical, and immunological parameters. by Songyan Zou (11399489)

Subjects:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Demographics and clinical features of healthy controls and primary Sjögren’s Syndrome patients. by Songyan Zou (11399489)

Subjects:

Anonymized clinical datasets (patient demographics, medical imaging, and laboratory test records). by Songyan Zou (11399489)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Correlation between biochemical indicators and Lymphocyte subsets in pSS patients. by Songyan Zou (11399489)

Subjects:

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... by Xiaofeng He (2618752)

Subjects:

Correlation between immune function indicators and Lymphocyte subsets in pSS patients. by Songyan Zou (11399489)

Subjects:

The global prevalence of gynecological diseases among women aged 15-49 years in 1990 and 2021, along with the trends and changes observed between these years. by Xiaofeng He (2618752)

Subjects:

Table 2_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx by Yulin Zhang (510822)

“…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …”

Table 1_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx by Yulin Zhang (510822)

“…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …”

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Threshold effect analysis of systemic inflammatory biomarkers on hepatitis C using two-piece wise linear regression. by Lu Han (151620)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects: